01 — What is it?
GIP + GLP-1 + glucagon receptor agonism. Phase 2 and multiple Phase 3 programs have reported substantial weight-loss effects. Remains investigational.
Database / Research Profiles / Retatrutide
RESEARCH PROFILE
RETATRUTIDE
LY3437943 • investigational triple receptor agonist
MetabolicStrong human clinical evidence
EVIDENCE SNAPSHOTSTRONG HUMAN CLINICAL EVIDENCE
Multiple randomized human trials; Phase 3 results reported in 2026. GI adverse events and heart-rate changes are important trial signals.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
Metabolic. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED
Multiple randomized human trials; Phase 3 results reported in 2026. GI adverse events and heart-rate changes are important trial signals.
04 — Mechanism / biology
GIP + GLP-1 + glucagon receptor agonism. Phase 2 and multiple Phase 3 programs have reported substantial weight-loss effects. Remains investigational.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.